anti-CD155 [PVR] (human), mAb (ANC2B2) (R-PE)
|Synonyms||PVR; Polio Virus Receptor; Necl-5|
|Product Type||Monoclonal Antibody|
|Source/Host||Purified from concentrated hybridoma tissue culture supernatant.|
|Immunogen/Antigen||Recombinant human CD155.|
Binds to human cell surface CD155 on U-937 cells, and binds to recombinant human CD155 in EIA.
|Purity Detail||Protein A purified.|
|Formulation||50mM Sodium Phosphate pH 7.5, 500mM Potassium Chloride, 150mM NaCl, 15% Glycerol, 0.2% BSA, 0.04% NaN3 (as a preservative).|
|Isotype Negative Control|
|Other Product Data||
Click here for Original Manufacturer Product Datasheet
|Declaration||Manufactured by Ancell Corporation.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
Do not freeze.
Protect from light.
|Use/Stability||Stable for at least 1 year after receipt when stored at +4°C.|
|Product Specification Sheet|
Human CD155 (Polio Virus Receptor, PVR, Necl-5) is a 70kd type I Ig superfamily molecule. It is involved in formation of intracellular junctions between epithelial cells. Its ligands include CD226 (DNAM-1), and CD96 (TACTILE). CD155 expression by tumor has been shown to be upregulated by nitric oxide. A soluble version of CD155 has been shown to exist. High CD155 expression has recently been exploited to use engineered poliovirus to treat glioblastoma.